Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345230 | 0.85 | CYP4F2 (0.40) | SMN1; SMN2CYP1A2TDP1CYP4F2CYP4A11 | |
| SCHEMBL23345256 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4E | |
| SCHEMBL19014335 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP1A2TDP1KDM4E | |
| SCHEMBL23995666 | 0.82 | CYP1A2 (0.38) | SMN1; SMN2CYP1A2CYP4F2CYP4A11 | |
| SCHEMBL23344999 | 0.80 | CYP1A2 (0.39) | SMN1; SMN2CYP1A2TDP1CYP4F2CYP4A11 | |
| SCHEMBL23995691 | 0.80 | CHRNB2 (0.43) | SMN1; SMN2 | |
| SCHEMBL23345258 | 0.76 | CYP2D6 (0.39) | CYP1A2CYP4F2CYP4A11 | |
| SCHEMBL18711302 | 0.73 | SPR (0.40) | SMN1; SMN2CYP1A2CYP4F2CYP4A11 | |
| SCHEMBL23345214 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL16907554 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | SMN1; SMN2 375/4885CYP1A2 1997/4885TDP1 2014/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | SMN1; SMN2 432/4885CYP1A2 2086/4885TDP1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.